Volume 102, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Epub ahead. doi: 10.1016/j.ijantimicag.2020.105949.
    [Google Scholar]
  2. Lim J, Jeon S, Shin H, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ, 2020. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35: 16.
    [Google Scholar]
  3. Cao B et al., 2020. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med. Epub ahead of print.
    [Google Scholar]
  4. Berry SM et al., 2017. A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatmetns: a model for pandemic response. Clin Trials 13: 2230.
    [Google Scholar]
  5. Iwuji CC et al., 2018. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV 5 e116e125.
    [Google Scholar]
  • Received : 08 Apr 2020
  • Accepted : 09 Apr 2020
  • Published online : 15 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error